Co-Diagnostics Completes Clinical and Analytical Studies in Preparation for FDA 510(k) Submission of Upper Respiratory Point-of-Care Test
Go back to Co-Diagnostics Completes Clinical and Analytical Studies in Preparation for FDA 510(k) Submission of Upper Respiratory Point-of-Care Test| (NASDAQ: CODX) | Delayed: 1.56 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.56 | 52 Week High | $ | |||
| Open | $1.56 | 52 Week Low | $ | |||
| Day High | $1.56 | P/E | N/A | |||
| Day Low | $1.56 | EPS | $ | |||
| Volume | 5,894 | |||||
